Results 181 to 190 of about 13,014,863 (297)

Development and validation of the manual disease activity score (MDAS) for rheumatoid arthritis. [PDF]

Rheumatol Immunol Res
Salim B, Nasim A, Jahan S, Perveen S, Samreen S, Gul H, Afzal A, Rizwan NUA, Ahmed M, Yasmin S.   +9 more
europepmc   +1 more source

Reexamining remission definitions in rheumatoid arthritis: considering the twenty-eight-joint Disease Activity Score, C-reactive protein level and patient global assessment. [PDF]

RMD Open, 2021
Felson D, Lacaille D, LaValley MP, Aletaha D.   +3 more
europepmc   +1 more source

Spatial and single‐nuclei transcriptomics reveals idiosyncratic and generic patterns in papillary and anaplastic thyroid cancers

Molecular Oncology, EarlyView.
Matched spatial transcriptomics and single‐nuclei RNA‐seq were generated for anaplastic and BRAFV600E papillary thyroid cancers revealing generic and tumor‐specific states occurring in cancer cells and in the tumor microenvironment. In this context, cancer dedifferentiation mirrored organoid maturation through ordered thyroid marker gain/loss ...
Adrien Tourneur, Joel Rodrigues Vitória, Manuel Saiselet, Ligia Craciun, Denis Larsimont, Anne Lefort, Frédérick Libert, Carine Maenhaut, Sabine Costagliola, Maxime Tarabichi, Mirian Romitti, Vincent Detours   +11 more
wiley   +1 more source

A score to settle—measuring Crohn's disease activity [PDF]

Nature Reviews Gastroenterology & Hepatology, 2013
openaire   +2 more sources

Correction: Population Pharmacokinetic-Pharmacodynamic Relationships of Sarilumab Using Disease Activity Score 28‑Joint C‑Reactive Protein and Absolute Neutrophil Counts in Patients with Rheumatoid Arthritis. [PDF]

Clin Pharmacokinet
Ma L, Xu C, Paccaly A, Kanamaluru V.
europepmc   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

Juvenile Arthritis Disease Activity Score [PDF]

, 2020
openaire   +1 more source

Validation of the Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) in a Chinese Cohort: Comparison with SLEDAI-2-K. [PDF]

Rheumatol Ther
Ding T, Li Y, Gao D, Ji L, Zhang X, Zhang Z.   +5 more
europepmc   +1 more source

Pharmacogenetics of TNF inhibitor response in rheumatoid arthritis utilizing the two-component disease activity score. [PDF]

Pharmacogenomics, 2020
Gilani SS, Nair N, Plant D, Hyrich K, Morgan AW, Morris AP, Wilson AG, Isaacs JD, Barton A, Bluett J, BRAGGSS Consortium.   +10 more
europepmc   +1 more source

Circulating microRNA signatures of cachexia and cancer in Canis familiaris as a comparative oncology model for human disease

Molecular Oncology, EarlyView.
Circulating microRNAs as biomarkers of cachexia and sex‐specific cancer in senior dogs. In 25 client‐owned dogs, four circulating miRNAs (miR‐15a, miR‐15b, miR‐16, miR‐140) were downregulated in cachexia, with miR‐16 the strongest individual biomarker (AUC = 0.899).
Soon‐Seok Park, Kyongman An, Gyeonghwa Kim, Soo‐Nyun Choi, Hong‐Ki Lee, Keun Hur, Kyu‐Shik Jeong   +6 more
wiley   +1 more source